|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:CBR1-ANKRD17 (FusionGDB2 ID:13410) |
Fusion Gene Summary for CBR1-ANKRD17 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CBR1-ANKRD17 | Fusion gene ID: 13410 | Hgene | Tgene | Gene symbol | CBR1 | ANKRD17 | Gene ID | 873 | 26057 |
| Gene name | carbonyl reductase 1 | ankyrin repeat domain 17 | |
| Synonyms | CBR|SDR21C1|hCBR1 | GTAR|MASK2|NY-BR-16 | |
| Cytomap | 21q22.12 | 4q13.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | carbonyl reductase [NADPH] 115-hydroxyprostaglandin dehydrogenaseNADPH-dependent carbonyl reductase 1carbonyl reductase (NADPH) 1epididymis secretory sperm binding proteinprostaglandin 9-ketoreductaseprostaglandin-E(2) 9-reductaseshort chain dehydr | ankyrin repeat domain-containing protein 17gene trap ankyrin repeat proteinserologically defined breast cancer antigen NY-BR-16 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | P16152 | O75179 | |
| Ensembl transtripts involved in fusion gene | ENST00000466328, ENST00000290349, ENST00000399191, ENST00000439427, ENST00000530908, | ENST00000330838, ENST00000358602, ENST00000509867, ENST00000514252, | |
| Fusion gene scores | * DoF score | 3 X 2 X 1=6 | 12 X 18 X 5=1080 |
| # samples | 3 | 21 | |
| ** MAII score | log2(3/6*10)=2.32192809488736 | log2(21/1080*10)=-2.36257007938471 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: CBR1 [Title/Abstract] AND ANKRD17 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | CBR1(37443269)-ANKRD17(73956613), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | CBR1-ANKRD17 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. CBR1-ANKRD17 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. CBR1-ANKRD17 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CBR1 | GO:0017144 | drug metabolic process | 18449627 |
| Hgene | CBR1 | GO:0042373 | vitamin K metabolic process | 18449627 |
| Hgene | CBR1 | GO:0055114 | oxidation-reduction process | 19442656 |
| Tgene | ANKRD17 | GO:0042742 | defense response to bacterium | 23711367 |
| Tgene | ANKRD17 | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 22328336 |
| Tgene | ANKRD17 | GO:0045087 | innate immune response | 23711367 |
| Tgene | ANKRD17 | GO:1900245 | positive regulation of MDA-5 signaling pathway | 22328336 |
| Tgene | ANKRD17 | GO:1900246 | positive regulation of RIG-I signaling pathway | 22328336 |
| Fusion gene breakpoints across CBR1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across ANKRD17 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS5.0 | N/A | DB034419 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
Top |
Fusion Gene ORF analysis for CBR1-ANKRD17 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 3UTR-3CDS | ENST00000466328 | ENST00000330838 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| 3UTR-3CDS | ENST00000466328 | ENST00000358602 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| 3UTR-3CDS | ENST00000466328 | ENST00000509867 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| 3UTR-intron | ENST00000466328 | ENST00000514252 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| 5CDS-intron | ENST00000290349 | ENST00000514252 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| 5CDS-intron | ENST00000399191 | ENST00000514252 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| 5CDS-intron | ENST00000439427 | ENST00000514252 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| 5CDS-intron | ENST00000530908 | ENST00000514252 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| Frame-shift | ENST00000290349 | ENST00000330838 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| Frame-shift | ENST00000290349 | ENST00000358602 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| Frame-shift | ENST00000290349 | ENST00000509867 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| Frame-shift | ENST00000399191 | ENST00000330838 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| Frame-shift | ENST00000399191 | ENST00000358602 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| Frame-shift | ENST00000399191 | ENST00000509867 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| Frame-shift | ENST00000530908 | ENST00000330838 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| Frame-shift | ENST00000530908 | ENST00000358602 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| Frame-shift | ENST00000530908 | ENST00000509867 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| In-frame | ENST00000439427 | ENST00000330838 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| In-frame | ENST00000439427 | ENST00000358602 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| In-frame | ENST00000439427 | ENST00000509867 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000439427 | CBR1 | chr21 | 37443269 | + | ENST00000358602 | ANKRD17 | chr4 | 73956613 | - | 4938 | 1002 | 625 | 95 | 176 |
| ENST00000439427 | CBR1 | chr21 | 37443269 | + | ENST00000509867 | ANKRD17 | chr4 | 73956613 | - | 2628 | 1002 | 625 | 95 | 176 |
| ENST00000439427 | CBR1 | chr21 | 37443269 | + | ENST00000330838 | ANKRD17 | chr4 | 73956613 | - | 2628 | 1002 | 625 | 95 | 176 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000439427 | ENST00000358602 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - | 0.50837797 | 0.49162203 |
| ENST00000439427 | ENST00000509867 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - | 0.22774474 | 0.77225524 |
| ENST00000439427 | ENST00000330838 | CBR1 | chr21 | 37443269 | + | ANKRD17 | chr4 | 73956613 | - | 0.22774474 | 0.77225524 |
Top |
Fusion Genomic Features for CBR1-ANKRD17 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for CBR1-ANKRD17 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr21:37443269/chr4:73956613) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CBR1 | ANKRD17 |
| FUNCTION: NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol (PubMed:18449627, PubMed:15799708, PubMed:17912391, PubMed:7005231). Can convert prostaglandin E to prostaglandin F2-alpha (By similarity). Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione (PubMed:18826943, PubMed:17344335). {ECO:0000250|UniProtKB:Q28960, ECO:0000269|PubMed:15799708, ECO:0000269|PubMed:17344335, ECO:0000269|PubMed:17912391, ECO:0000269|PubMed:18449627, ECO:0000269|PubMed:18826943, ECO:0000269|PubMed:7005231}. | FUNCTION: Could play pivotal roles in cell cycle and DNA regulation (PubMed:19150984). Involved in innate immune defense against viruse by positively regulating the viral dsRNA receptors DDX58 and IFIH1 signaling pathways (PubMed:22328336). Involves in NOD2- and NOD1-mediated responses to bacteria suggesting a role in innate antibacterial immune pathways too (PubMed:23711367). Target of enterovirus 71 which is the major etiological agent of HFMD (hand, foot and mouth disease) (PubMed:17276651). Could play a central role for the formation and/or maintenance of the blood vessels of the circulation system (By similarity). {ECO:0000250|UniProtKB:Q99NH0, ECO:0000269|PubMed:17276651, ECO:0000269|PubMed:19150984, ECO:0000269|PubMed:22328336, ECO:0000269|PubMed:23711367}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1442_1526 | 0 | 2353.0 | Coiled coil | Ontology_term=ECO:0000255 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1442_1526 | 0 | 2604.0 | Coiled coil | Ontology_term=ECO:0000255 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1603_1700 | 0 | 2353.0 | Compositional bias | Note=Ser-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1950_2106 | 0 | 2353.0 | Compositional bias | Note=Ser-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1966_2033 | 0 | 2353.0 | Compositional bias | Note=Thr-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 858_1008 | 0 | 2353.0 | Compositional bias | Note=Gln-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 96_110 | 0 | 2353.0 | Compositional bias | Note=Gly-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1603_1700 | 0 | 2604.0 | Compositional bias | Note=Ser-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1950_2106 | 0 | 2604.0 | Compositional bias | Note=Ser-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1966_2033 | 0 | 2604.0 | Compositional bias | Note=Thr-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 858_1008 | 0 | 2604.0 | Compositional bias | Note=Gln-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 96_110 | 0 | 2604.0 | Compositional bias | Note=Gly-rich | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1725_1789 | 0 | 2353.0 | Domain | KH | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1725_1789 | 0 | 2604.0 | Domain | KH | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1082_1111 | 0 | 2353.0 | Repeat | Note=ANK 16 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1115_1144 | 0 | 2353.0 | Repeat | Note=ANK 17 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1149_1178 | 0 | 2353.0 | Repeat | Note=ANK 18 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1182_1211 | 0 | 2353.0 | Repeat | Note=ANK 19 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1217_1246 | 0 | 2353.0 | Repeat | Note=ANK 20 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1251_1280 | 0 | 2353.0 | Repeat | Note=ANK 21 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1284_1313 | 0 | 2353.0 | Repeat | Note=ANK 22 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1319_1348 | 0 | 2353.0 | Repeat | Note=ANK 23 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1352_1381 | 0 | 2353.0 | Repeat | Note=ANK 24 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 1385_1414 | 0 | 2353.0 | Repeat | Note=ANK 25 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 233_262 | 0 | 2353.0 | Repeat | Note=ANK 1 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 266_295 | 0 | 2353.0 | Repeat | Note=ANK 2 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 300_329 | 0 | 2353.0 | Repeat | Note=ANK 3 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 333_362 | 0 | 2353.0 | Repeat | Note=ANK 4 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 366_395 | 0 | 2353.0 | Repeat | Note=ANK 5 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 400_429 | 0 | 2353.0 | Repeat | Note=ANK 6 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 433_462 | 0 | 2353.0 | Repeat | Note=ANK 7 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 466_495 | 0 | 2353.0 | Repeat | Note=ANK 8 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 499_528 | 0 | 2353.0 | Repeat | Note=ANK 9 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 533_562 | 0 | 2353.0 | Repeat | Note=ANK 10 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 563_592 | 0 | 2353.0 | Repeat | Note=ANK 11 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 596_625 | 0 | 2353.0 | Repeat | Note=ANK 12 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 629_658 | 0 | 2353.0 | Repeat | Note=ANK 13 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 663_692 | 0 | 2353.0 | Repeat | Note=ANK 14 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000330838 | 0 | 33 | 696_725 | 0 | 2353.0 | Repeat | Note=ANK 15 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1082_1111 | 0 | 2604.0 | Repeat | Note=ANK 16 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1115_1144 | 0 | 2604.0 | Repeat | Note=ANK 17 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1149_1178 | 0 | 2604.0 | Repeat | Note=ANK 18 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1182_1211 | 0 | 2604.0 | Repeat | Note=ANK 19 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1217_1246 | 0 | 2604.0 | Repeat | Note=ANK 20 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1251_1280 | 0 | 2604.0 | Repeat | Note=ANK 21 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1284_1313 | 0 | 2604.0 | Repeat | Note=ANK 22 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1319_1348 | 0 | 2604.0 | Repeat | Note=ANK 23 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1352_1381 | 0 | 2604.0 | Repeat | Note=ANK 24 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 1385_1414 | 0 | 2604.0 | Repeat | Note=ANK 25 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 233_262 | 0 | 2604.0 | Repeat | Note=ANK 1 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 266_295 | 0 | 2604.0 | Repeat | Note=ANK 2 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 300_329 | 0 | 2604.0 | Repeat | Note=ANK 3 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 333_362 | 0 | 2604.0 | Repeat | Note=ANK 4 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 366_395 | 0 | 2604.0 | Repeat | Note=ANK 5 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 400_429 | 0 | 2604.0 | Repeat | Note=ANK 6 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 433_462 | 0 | 2604.0 | Repeat | Note=ANK 7 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 466_495 | 0 | 2604.0 | Repeat | Note=ANK 8 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 499_528 | 0 | 2604.0 | Repeat | Note=ANK 9 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 533_562 | 0 | 2604.0 | Repeat | Note=ANK 10 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 563_592 | 0 | 2604.0 | Repeat | Note=ANK 11 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 596_625 | 0 | 2604.0 | Repeat | Note=ANK 12 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 629_658 | 0 | 2604.0 | Repeat | Note=ANK 13 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 663_692 | 0 | 2604.0 | Repeat | Note=ANK 14 | |
| Tgene | ANKRD17 | chr21:37443269 | chr4:73956613 | ENST00000358602 | 0 | 34 | 696_725 | 0 | 2604.0 | Repeat | Note=ANK 15 |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | CBR1 | chr21:37443269 | chr4:73956613 | ENST00000290349 | + | 1 | 3 | 10_34 | 0 | 278.0 | Nucleotide binding | NADP |
| Hgene | CBR1 | chr21:37443269 | chr4:73956613 | ENST00000290349 | + | 1 | 3 | 194_198 | 0 | 278.0 | Nucleotide binding | NADP |
| Hgene | CBR1 | chr21:37443269 | chr4:73956613 | ENST00000290349 | + | 1 | 3 | 231_233 | 0 | 278.0 | Nucleotide binding | NADP |
| Hgene | CBR1 | chr21:37443269 | chr4:73956613 | ENST00000290349 | + | 1 | 3 | 63_64 | 0 | 278.0 | Nucleotide binding | NADP |
| Hgene | CBR1 | chr21:37443269 | chr4:73956613 | ENST00000290349 | + | 1 | 3 | 193_194 | 0 | 278.0 | Region | Note=Glutathione binding |
| Hgene | CBR1 | chr21:37443269 | chr4:73956613 | ENST00000290349 | + | 1 | 3 | 95_97 | 0 | 278.0 | Region | Note=Glutathione binding |
Top |
Fusion Gene Sequence for CBR1-ANKRD17 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >13410_13410_1_CBR1-ANKRD17_CBR1_chr21_37443269_ENST00000439427_ANKRD17_chr4_73956613_ENST00000330838_length(transcript)=2628nt_BP=1002nt ACGACCGCCAGACTCGAGCAGTCTCTGGAACACGCTGCGGGGCTCCCGGGCCTGAGCCAGGTCTGTTCTCCACGCAGGTGTTCCGCGCGC CCCGTTCAGCCATGTCGTCCGGCATCCATGTAGCGCTGGTGACTGGAGGCAACAAGGGCATCGGCTTGGCCATCGTGCGCGACCTGTGCC GGCTGTTCTCGGGGGACGTGGTGCTCACGGCGCGGGACGTGACGCGGGGCCAGGCGGCCGTACAGCAGCTGCAGGCGGAGGGCCTGAGCC CGCGCTTCCACCAGCTGGACATCGACGATCTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGGGGCCTGGACGTGC TGGTCAACAACGCGGGCATCGCCTTCAAGGTATTCAAGCTGAAGTGACGATGAAAACAAATTTCTTTGGTACCCGAGATGTGTGCACAGA ATTACTCCCTCTAATAAAACCCCAAGGTGAGTCTGATGGGAAACAGCGCACCTTCTCTTTGGGGCTTGATTTGGCCCCTGCTTGCCTGGG ATTTCTCCTGCAGGCTCCTGCTTCCTCTCCATGCTGCACGTGCACTGACCTCTGTGCTTTTTCTCCTGCCAGCTGATATGTGCCATTTTG CCTCAGGACTTTGTCCTCACTTCTCCCACTCCCATGGCCATTCGTCCTCCCTGTCGCACTGGTCTTTGCACACCTGGCTGACTCTCATCC TTCAGGTCTTAGCTCAAACGTCTCCTGAGAGATGCTCTTTATTTGCTCCATTCCCCTCTGCGTGGGAGTCCATCCTGTACCCTTTCTCTG CTCTTTCAGAGAGATCTTATTCAGGCTGGTGGAGGCTTTACTACCACCAGTTCATTAGGCCCTTCTAATACCTGTCACCTGTCTGAAACA CTCCTTAAGCTCCCAACCACATGGTTGTCTTGCTGCCTTTCCATCTCTTCCTGATGCCTTTCCCCACAATCTAAGATATTTCCAGAGGAT CCCTATCCTTTTGTGTGGACTGGACCCTGGGCACCTCACATGAACAGTGTGCATATGAACCAGCTTGGCTGATGAGGATCAGCTTGTTAG CCTGCAGATTCCTTTTCATTTGGAGGAAATCACAAGTGGCCGAAAAAAAAAATTATGCTCCCAAATCATTCTACTGATGTGCTTGACTGA AGTGTGTAGGCTTTTTGCAGAAGATCTTACTAACTGACCTATTTTCTGTGAACATTTGTGACTGCCCATTCCCCATCATCATCCGTTTTA CCTTAGTTAGCATTTTTCTTATCATTTTTCTTTTTTTCTTTCCCTCTTCCCCTTTGGACATAACTTTCTGTTGAAGCTGTTCTTTGGCTG GTTGGTTTTAGTACTGTAAACTGCTTCTGAGCAAACACGGAAATTTAGCAAAATTATGTAAACTTGATCCTGAAGTTTTAGAATGGCAAA TAAATGTACAATTGTTTACATAACAGAAAAGGCTAAGCAGAAAGTAAATTTCAATATGTCAGTATAGAGGCTCTACTTTATGTAGACTTA AATTAATGTGAGATATGTACCTTCATATTCAGAAATCTGGATGTTTCCTTCATACATTAAACTATTAATAAGCATAAGGTATGCCTTTTT CTGTGTATGGGAATGCAATGATTCCTCCAGTAGCACCTATCCCTGATGGTGCTGGAGGACCCATATTTAATGGCCCTCATGCTGCAGACC CTTCTTGGAACTCACTGATAAAGATGGTTTCCAGCTCCACGGAAAATAATGGCCCTCAAACGACAAAGTAGACTGGTGTAACCCTGGGAT GGGAAATCCTATGATCCACAGACCGATGTCTGACCCAGGAGTATTTTCACAACATCAAGCAATGGAGCGAGATAGTACAGGAATTGTAAC TCCTTCTGGTACATTCCATCAGCATGTTCCTGCAGGCTACATGGACTTTCCTAAAGTTGGGATTCTTCTGCACAGTCAGTATCCTCGGGA GTTCGTGCACCATCTCCTGCCCCATCATCAGTACCGTTAGGGTCAGAAAAGCCCAGCAATGTGTCTCAGGACAGGAAAGTTCCAGTCCCT ATTGGGACTGAACGTTCTGCACGTATCAGGCAAACTGGAACGTCAGCTCCATCTGTTATTGGGAGCAATTTGTCTACATCAGTAGGACAT AGTGGCATCTGGTCCTTTGAAGGGATTGGTGGCAATCAAGGTATTGTCAATATGGACTCGCCATATGGTTCTGTAACACCTTCTTCAACA CATTTGGGAAACTTTGCTTCAAACATTTCAGGAGGTCAGATGTACGGACCTGGGGCACCCCTTGGAGGAGCACCCGCAGCTGCTAACTTT AACAGACAACATTTTTCCCCGCTTAGTTTGTTGACTCCGTGTTCATCAGCATCAAATGTTTCAGTGCCCCCTTACCATTTGGGCCCTTTA GCACATTGTTTGAAAACAGCCCTACTTCTGCTCATGCCTTCTGGGGAGGATCTGTTGTTTCATCTCAGTCAACACCAGAATCTATGCTAT CAGGAAAATCCTCATATTTGCCAAATTCAGATCCTTTACATCAGTCTGATACTTCCAAAGCTCCAGGTTTTAGACCACCATTACAGAGAC >13410_13410_1_CBR1-ANKRD17_CBR1_chr21_37443269_ENST00000439427_ANKRD17_chr4_73956613_ENST00000330838_length(amino acids)=176AA_BP= MAHISWQEKKHRGQCTCSMERKQEPAGEIPGKQGPNQAPKRRCAVSHQTHLGVLLEGVILCTHLGYQRNLFSSSLQLEYLEGDARVVDQH -------------------------------------------------------------- >13410_13410_2_CBR1-ANKRD17_CBR1_chr21_37443269_ENST00000439427_ANKRD17_chr4_73956613_ENST00000358602_length(transcript)=4938nt_BP=1002nt ACGACCGCCAGACTCGAGCAGTCTCTGGAACACGCTGCGGGGCTCCCGGGCCTGAGCCAGGTCTGTTCTCCACGCAGGTGTTCCGCGCGC CCCGTTCAGCCATGTCGTCCGGCATCCATGTAGCGCTGGTGACTGGAGGCAACAAGGGCATCGGCTTGGCCATCGTGCGCGACCTGTGCC GGCTGTTCTCGGGGGACGTGGTGCTCACGGCGCGGGACGTGACGCGGGGCCAGGCGGCCGTACAGCAGCTGCAGGCGGAGGGCCTGAGCC CGCGCTTCCACCAGCTGGACATCGACGATCTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGGGGCCTGGACGTGC TGGTCAACAACGCGGGCATCGCCTTCAAGGTATTCAAGCTGAAGTGACGATGAAAACAAATTTCTTTGGTACCCGAGATGTGTGCACAGA ATTACTCCCTCTAATAAAACCCCAAGGTGAGTCTGATGGGAAACAGCGCACCTTCTCTTTGGGGCTTGATTTGGCCCCTGCTTGCCTGGG ATTTCTCCTGCAGGCTCCTGCTTCCTCTCCATGCTGCACGTGCACTGACCTCTGTGCTTTTTCTCCTGCCAGCTGATATGTGCCATTTTG CCTCAGGACTTTGTCCTCACTTCTCCCACTCCCATGGCCATTCGTCCTCCCTGTCGCACTGGTCTTTGCACACCTGGCTGACTCTCATCC TTCAGGTCTTAGCTCAAACGTCTCCTGAGAGATGCTCTTTATTTGCTCCATTCCCCTCTGCGTGGGAGTCCATCCTGTACCCTTTCTCTG CTCTTTCAGAGAGATCTTATTCAGGCTGGTGGAGGCTTTACTACCACCAGTTCATTAGGCCCTTCTAATACCTGTCACCTGTCTGAAACA CTCCTTAAGCTCCCAACCACATGGTTGTCTTGCTGCCTTTCCATCTCTTCCTGATGCCTTTCCCCACAATCTAAGATATTTCCAGAGGAT CCCTATCCTTTTGTGTGGACTGGACCCTGGGCACCTCACATGAACAGTGTGCATATGAACCAGCTTGGCTGATGAGGATCAGCTTGTTAG CCTGCAGATTCCTTTTCATTTGGAGGAAATCACAAGTGGCCGAAAAAAAAAATTATGCTCCCAAATCATTCTACTGATGTGCTTGACTGA AGTGTGTAGGCTTTTTGCAGAAGATCTTACTAACTGACCTATTTTCTGTGAACATTTGTGACTGCCCATTCCCCATCATCATCCGTTTTA CCTTAGTTAGCATTTTTCTTATCATTTTTCTTTTTTTCTTTCCCTCTTCCCCTTTGGACATAACTTTCTGTTGAAGCTGTTCTTTGGCTG GTTGGTTTTAGTACTGTAAACTGCTTCTGAGCAAACACGGAAATTTAGCAAAATTATGTAAACTTGATCCTGAAGTTTTAGAATGGCAAA TAAATGTACAATTGTTTACATAACAGAAAAGGCTAAGCAGAAAGTAAATTTCAATATGTCAGTATAGAGGCTCTACTTTATGTAGACTTA AATTAATGTGAGATATGTACCTTCATATTCAGAAATCTGGATGTTTCCTTCATACATTAAACTATTAATAAGCATAACTTTTCTACTGGT GTAATTTAAGTATAAAGTAAAATAATGGGCATTATCATTGGATGTTTCCCCACATTGGCTTTTAAAATACCCATCTTGCTTTCTTTTTGG TTTATTTGTAGCAAGGCACATATAGAAGAAGAAATTTCTGGCTTTTCCATGTTGTTTTATTACCTTTTCTCACTTTTAAAACTAATACAG ACTTATCTCCTCACTCCTTTTTCTCTCCTTACCTTTACCACTAATACCAGTAAAATTATCTTTCTGATAGTGAAAAGGTTCTGTCAAGAT TTTCACTGTAATGGCTGCTACAGAGATGGACCATCTTCATCATCACCAGTGGTTTCTTCTAATTATAAAATGTTTAAACTTTCTGAGAAT TTAAAAAGCCACCACTGTTCCCAGTCAGCATATACAAGCTCTTAATATTCTGTTTATTAAATAATTCAATGTACTATTTTATATTGGATG ATATTGATTCTTAACATTGGCTTTTCAGTCATCAACAGTCAACATAAAAATTTCAATTTTCAGTAATTTAGTGGAAAATATCTTATTTCT TTTTTCAATTTTAAAGGCTTCCTGCTTTTTTACCCTTGTATATTATCAGTGAAAAGGATCAACAGTTAATTTGAGCCAAGTAATAAAAGA AATTCTGCATTTGTCACGAAGACAATTTATGGTAGACAGATAAATACACAGATTACAGTGTAAAGTCTCCATTTAACCTGTTTATAAAAG ATACAAGGCCACACTAAACTACTCAGTGGGATTTATATATTCCATCCACTTGAAACAATAAACAGTAATGTATCCAAGAAGATTATGTGT CCTACCCTGTCTCATGGAAAAATTAATTATATGGTTGAAATGTAAAAGAAAGTAAGCATAAAAATCGAGTAATGTATATATCAATTTGTC TTCTTTTTTTTTAATTAGACATAAAATTTCACACTGGTAAAACATAAAAACTAACTAAAATTCATATAAATCACCTAGAGTTGATGATAT TAACATGGTTCCTTGGTTGTCAAGTAAATCAAATGATTTCTTCCATCTGAGTAAAGAGTAAAGCCTGAGTAAAGAGTAAAAAGATGACTT CTCAAACATATCCAGAAATTTGTAAACAGTACACTCATATCTTTTAGTTTAAGAAGTGGTCTTAAAATATATAAATTTGTTTTTCCACCT ATGTTTAATATGCCCAAATTTAAAGGGAGAGCTAAAAGACAGCCTACAAATAAATATAGCTATGAAATAAAATTATAGCACTTTACTAAA AAAGGGATGTAATAATGTTATTTAACGAAGTATTTTATATATGACTTGCCACTATTCTATACATAAAATTTTTTTTCTTAATTCTTTCCT GTGTTAACTAGGGTTATTTTCTATTTAAGGTAATCCTGCTGGAGAACAGATGCTATCCAATATTTATTACAACACATGAGTTGTGTTGTT TCACAATACTGAATTTCTTAGGTGAGGTATTTTATTTAAAAAGGAGGGGGAAAACTCCTATATTTTCTTGACTTCAAACCTGTGGGGCCA GGGGATATAGATTGAAATGCTCCGTATTTAGTCTTGGGGATCAGGCTTGTTTAGTACAATACCATGGTTTTAGAAGTCTGTACTAGGAAC ATTTTTAAAATACATTTTTTATATTTCAGATGTAATGCAGTGCACTTTTATTTGAACAATAAAAAAACCCATAACTTTTTGAGACCATGA AGGTCTTTTATTTTTTAATTTTGAAAATATGTGGTATGTGTATATGCAGACTACATCATTGTTTTAAGAAATGATTTAACTCTTGGACAT TACACTTGGGTTAGTTCACACCTTAAATCCCCAAGTAGTTAATATCTCAATTATTGTATAATCAGTTTATACCATCCATTCCCAACAAAA TTCCACATTTCATGCCTTTTCAACATACATTTCAACATAATCAACATATTTACAAACACTGACTTCACTGTTTATAAAGAAGAAATTTCC CCTCCTATTTCCCATTACTGAAAAGTCAAGTCATTTTTATTGATACATGAAAATTAATTTTTTTGTAAATGACTACGTATAGTCATTTTT CTCCTTTGGAAAAGGTAAATAGCTTATTAACTAATCCTGTCTTGTTCTTCACAAAAATAATAGTCCATCCGTGTTTTGACTCAAATAACC TAAATACACATTTTGTAAAAATTTTGTACCCTATATTACTTATTTTTAAAACAGTACAGTGTTAGACTAAACAGGAAAACTCAAAGTTAT AAAATCTCTTCAGATCCTCTAGTTTATTAAATCTATTTTCATGTTGAGGTATGCCTTTTTCTGTGTATGGGAATGCAATGATTCCTCCAG TAGCACCTATCCCTGATGGTGCTGGAGGACCCATATTTAATGGCCCTCATGCTGCAGACCCTTCTTGGAACTCACTGATAAAGATGGTTT CCAGCTCCACGGAAAATAATGGCCCTCAAACGACAAAGTAGACTGGTGTAACCCTGGGATGGGAAATCCTATGATCCACAGACCGATGTC TGACCCAGGAGTATTTTCACAACATCAAGCAATGGAGCGAGATAGTACAGGAATTGTAACTCCTTCTGGTACATTCCATCAGCATGTTCC TGCAGGCTACATGGACTTTCCTAAAGTTGGGATTCTTCTGCACAGTCAGTATCCTCGGGAGTTCGTGCACCATCTCCTGCCCCATCATCA GTACCGTTAGGGTCAGAAAAGCCCAGCAATGTGTCTCAGGACAGGAAAGTTCCAGTCCCTATTGGGACTGAACGTTCTGCACGTATCAGG CAAACTGGAACGTCAGCTCCATCTGTTATTGGGAGCAATTTGTCTACATCAGTAGGACATAGTGGCATCTGGTCCTTTGAAGGGATTGGT GGCAATCAAGGTATTGTCAATATGGACTCGCCATATGGTTCTGTAACACCTTCTTCAACACATTTGGGAAACTTTGCTTCAAACATTTCA GGAGGTCAGATGTACGGACCTGGGGCACCCCTTGGAGGAGCACCCGCAGCTGCTAACTTTAACAGACAACATTTTTCCCCGCTTAGTTTG TTGACTCCGTGTTCATCAGCATCAAATGTTTCAGTGCCCCCTTACCATTTGGGCCCTTTAGCACATTGTTTGAAAACAGCCCTACTTCTG CTCATGCCTTCTGGGGAGGATCTGTTGTTTCATCTCAGTCAACACCAGAATCTATGCTATCAGGAAAATCCTCATATTTGCCAAATTCAG >13410_13410_2_CBR1-ANKRD17_CBR1_chr21_37443269_ENST00000439427_ANKRD17_chr4_73956613_ENST00000358602_length(amino acids)=176AA_BP= MAHISWQEKKHRGQCTCSMERKQEPAGEIPGKQGPNQAPKRRCAVSHQTHLGVLLEGVILCTHLGYQRNLFSSSLQLEYLEGDARVVDQH -------------------------------------------------------------- >13410_13410_3_CBR1-ANKRD17_CBR1_chr21_37443269_ENST00000439427_ANKRD17_chr4_73956613_ENST00000509867_length(transcript)=2628nt_BP=1002nt ACGACCGCCAGACTCGAGCAGTCTCTGGAACACGCTGCGGGGCTCCCGGGCCTGAGCCAGGTCTGTTCTCCACGCAGGTGTTCCGCGCGC CCCGTTCAGCCATGTCGTCCGGCATCCATGTAGCGCTGGTGACTGGAGGCAACAAGGGCATCGGCTTGGCCATCGTGCGCGACCTGTGCC GGCTGTTCTCGGGGGACGTGGTGCTCACGGCGCGGGACGTGACGCGGGGCCAGGCGGCCGTACAGCAGCTGCAGGCGGAGGGCCTGAGCC CGCGCTTCCACCAGCTGGACATCGACGATCTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAGTACGGGGGCCTGGACGTGC TGGTCAACAACGCGGGCATCGCCTTCAAGGTATTCAAGCTGAAGTGACGATGAAAACAAATTTCTTTGGTACCCGAGATGTGTGCACAGA ATTACTCCCTCTAATAAAACCCCAAGGTGAGTCTGATGGGAAACAGCGCACCTTCTCTTTGGGGCTTGATTTGGCCCCTGCTTGCCTGGG ATTTCTCCTGCAGGCTCCTGCTTCCTCTCCATGCTGCACGTGCACTGACCTCTGTGCTTTTTCTCCTGCCAGCTGATATGTGCCATTTTG CCTCAGGACTTTGTCCTCACTTCTCCCACTCCCATGGCCATTCGTCCTCCCTGTCGCACTGGTCTTTGCACACCTGGCTGACTCTCATCC TTCAGGTCTTAGCTCAAACGTCTCCTGAGAGATGCTCTTTATTTGCTCCATTCCCCTCTGCGTGGGAGTCCATCCTGTACCCTTTCTCTG CTCTTTCAGAGAGATCTTATTCAGGCTGGTGGAGGCTTTACTACCACCAGTTCATTAGGCCCTTCTAATACCTGTCACCTGTCTGAAACA CTCCTTAAGCTCCCAACCACATGGTTGTCTTGCTGCCTTTCCATCTCTTCCTGATGCCTTTCCCCACAATCTAAGATATTTCCAGAGGAT CCCTATCCTTTTGTGTGGACTGGACCCTGGGCACCTCACATGAACAGTGTGCATATGAACCAGCTTGGCTGATGAGGATCAGCTTGTTAG CCTGCAGATTCCTTTTCATTTGGAGGAAATCACAAGTGGCCGAAAAAAAAAATTATGCTCCCAAATCATTCTACTGATGTGCTTGACTGA AGTGTGTAGGCTTTTTGCAGAAGATCTTACTAACTGACCTATTTTCTGTGAACATTTGTGACTGCCCATTCCCCATCATCATCCGTTTTA CCTTAGTTAGCATTTTTCTTATCATTTTTCTTTTTTTCTTTCCCTCTTCCCCTTTGGACATAACTTTCTGTTGAAGCTGTTCTTTGGCTG GTTGGTTTTAGTACTGTAAACTGCTTCTGAGCAAACACGGAAATTTAGCAAAATTATGTAAACTTGATCCTGAAGTTTTAGAATGGCAAA TAAATGTACAATTGTTTACATAACAGAAAAGGCTAAGCAGAAAGTAAATTTCAATATGTCAGTATAGAGGCTCTACTTTATGTAGACTTA AATTAATGTGAGATATGTACCTTCATATTCAGAAATCTGGATGTTTCCTTCATACATTAAACTATTAATAAGCATAAGGTATGCCTTTTT CTGTGTATGGGAATGCAATGATTCCTCCAGTAGCACCTATCCCTGATGGTGCTGGAGGACCCATATTTAATGGCCCTCATGCTGCAGACC CTTCTTGGAACTCACTGATAAAGATGGTTTCCAGCTCCACGGAAAATAATGGCCCTCAAACGACAAAGTAGACTGGTGTAACCCTGGGAT GGGAAATCCTATGATCCACAGACCGATGTCTGACCCAGGAGTATTTTCACAACATCAAGCAATGGAGCGAGATAGTACAGGAATTGTAAC TCCTTCTGGTACATTCCATCAGCATGTTCCTGCAGGCTACATGGACTTTCCTAAAGTTGGGATTCTTCTGCACAGTCAGTATCCTCGGGA GTTCGTGCACCATCTCCTGCCCCATCATCAGTACCGTTAGGGTCAGAAAAGCCCAGCAATGTGTCTCAGGACAGGAAAGTTCCAGTCCCT ATTGGGACTGAACGTTCTGCACGTATCAGGCAAACTGGAACGTCAGCTCCATCTGTTATTGGGAGCAATTTGTCTACATCAGTAGGACAT AGTGGCATCTGGTCCTTTGAAGGGATTGGTGGCAATCAAGGTATTGTCAATATGGACTCGCCATATGGTTCTGTAACACCTTCTTCAACA CATTTGGGAAACTTTGCTTCAAACATTTCAGGAGGTCAGATGTACGGACCTGGGGCACCCCTTGGAGGAGCACCCGCAGCTGCTAACTTT AACAGACAACATTTTTCCCCGCTTAGTTTGTTGACTCCGTGTTCATCAGCATCAAATGTTTCAGTGCCCCCTTACCATTTGGGCCCTTTA GCACATTGTTTGAAAACAGCCCTACTTCTGCTCATGCCTTCTGGGGAGGATCTGTTGTTTCATCTCAGTCAACACCAGAATCTATGCTAT CAGGAAAATCCTCATATTTGCCAAATTCAGATCCTTTACATCAGTCTGATACTTCCAAAGCTCCAGGTTTTAGACCACCATTACAGAGAC >13410_13410_3_CBR1-ANKRD17_CBR1_chr21_37443269_ENST00000439427_ANKRD17_chr4_73956613_ENST00000509867_length(amino acids)=176AA_BP= MAHISWQEKKHRGQCTCSMERKQEPAGEIPGKQGPNQAPKRRCAVSHQTHLGVLLEGVILCTHLGYQRNLFSSSLQLEYLEGDARVVDQH -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for CBR1-ANKRD17 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CBR1-ANKRD17 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for CBR1-ANKRD17 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies